What You Should Know:
SciBase Holding AB, a developer of augmented intelligence-based solutions for skin disorders, has entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations.
– Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. The collaboration emphasizes the significance of early testing and treatment to improve survival rates.
– The collaboration aims to bring Nevisense, the only FDA-approved AI-driven test for early melanoma detection at point-of-care, to the patients of the Skin and Cancer Institute during routine skin exams. Clinicians at several Skin and Cancer Institute locations in California will have access to state-of-the-art melanoma detection technology at the point of care through Nevisense.
About Skin and Cancer Institute
The Skin and Cancer Institute is a world-renowned dermatology practice group consisting of dermatologists and skin cancer surgeons. It is one of the largest dermatology groups in the country, with more than 50 offices across California, Arizona, and Nevada.
